Cyanocobalamin (B12).

Methionine synthase takes a methyl group from 5-MTHF and passes it through cobalamin to homocysteine. Without B12 the folate stays stuck in its methylated form.

Folate and B12 hand a methyl group between them at the same enzyme. Low B12 blocks folate from re-entering the rest of the cycle.

B12 supports remethylation back to methionine while B6 supports transsulfuration toward cysteine. Homocysteine formulas carry both because each closes a different exit.

Cyanocobalamin is a stable precursor that the cell converts into adenosylcobalamin and methylcobalamin. Supplying the adenosyl form directly bypasses that conversion for the mitochondrial enzyme.

Methionine synthase reductase is an FAD enzyme that returns the cobalamin cofactor to its reduced state after it oxidises. Riboflavin therefore keeps the B12 dependent step turning over.

B12 supports DNA synthesis in dividing erythroid cells while iron builds the heme. A shortfall in either limits normal red cell production.

The cubilin receptor that takes up the B12 intrinsic factor complex in the ileum requires calcium. Calcium availability is part of the absorption step itself.

Methionine synthase restores methionine, which is then adenosylated to SAM. B12 status feeds the pool the methyl donor is drawn from.

High dose ascorbic acid can break down cyanocobalamin when the two sit in the same aqueous mixture. Separating the doses or the dosage forms keeps the cobalamin intact.

Both methionine synthase and betaine-homocysteine methyltransferase are zinc metalloenzymes; the zinc atom activates the homocysteine thiol for methyl transfer. B12 supplies the methyl carrier for one of those enzymes, zinc holds the substrate in place. Cofactor biochemistry, not a tested pairing.

Homocysteine can be remethylated by methionine synthase, which needs B12 and folate, or by BHMT using betaine, which needs neither. When the B12-dependent route is limited the betaine route carries more of the load in liver and kidney. That partial redundancy is why a normal homocysteine reading does not by itself confirm adequate B12 status.

B12 in food is bound to protein and has to be freed by gastric acid and pepsin before intrinsic factor can pick it up. Crystalline B12 in a supplement is already free, so it bypasses that step. This interaction therefore matters for dietary B12 rather than for the tablet itself, and it is the reason low gastric acid affects food B12 more than supplemental B12.

Pepsin, activated by gastric acid, cleaves the food proteins that hold B12, allowing it to transfer to haptocorrin and then to intrinsic factor. Without that proteolysis, dietary B12 stays bound. Supplemental crystalline cyanocobalamin does not require this step.

When B12 is replete after a long shortfall, a burst of new cell production draws potassium into cells and serum potassium can fall in the first days. This is well recognised in supervised repletion of severe shortfall, not in ordinary oral supplementation. It is a monitoring consideration rather than a reason to take the two together.

When B12 is short, folate becomes stuck as 5-methyltetrahydrofolate because methionine synthase cannot release it. High-dose folic acid can normalise the blood cell picture while the B12-dependent neurological consequences continue unaddressed. That is why folic acid and B12 are assessed together rather than one being used to correct the other.

High-dose biotin interferes with many laboratory immunoassays, including some serum B12 assays, by saturating the streptavidin capture chemistry. The result is a distorted number rather than a change in actual B12 status. Stopping high-dose biotin before blood work is the usual instruction.

Cobalamin is made only by bacteria and archaea, and some gut species produce it. The catch is that colonic synthesis sits distal to the ileal receptor that absorbs it, so what colonic bacteria make is largely not taken up. Some analogues produced by gut organisms are also inactive in humans while still reading on certain assays.

All cobalamin forms are stripped to a common cob(II)alamin intermediate inside the cell and then rebuilt into methylcobalamin for methionine synthase or adenosylcobalamin for methylmalonyl-CoA mutase. Taking cyanocobalamin and methylcobalamin together is redundant at that intermediate step rather than complementary. The difference between them is the leaving group and the tissue retention, not the destination.

Hydroxocobalamin carries a hydroxyl group rather than a cyanide group and binds plasma proteins more tightly, which is why injectable repletion protocols often use it. It converges on the same cob(II)alamin intermediate as cyanocobalamin. Combining the two adds cobalamin content, not a second mechanism.

Adenosylcobalamin-dependent methylmalonyl-CoA mutase feeds propionyl carbon into the citric acid cycle at succinyl-CoA, while thiamine pyrophosphate serves the dehydrogenase complexes that feed the same cycle. Both shortfalls show as impaired mitochondrial carbon handling. Their roles are adjacent, not interchangeable.

Activated charcoal adsorbs a broad range of molecules in the gut without selectivity, and a water-soluble vitamin taken at the same time can be carried out with it. Dose separation of several hours is the ordinary answer. This is a timing issue, not a contraindication.

Methionine synthase periodically loses its methyl group and must be reactivated by methionine synthase reductase, a flavoprotein that requires FAD, made from riboflavin. Without that reactivation the B12-dependent enzyme goes quiet even with cobalamin present. This is why riboflavin status shows up in homocysteine analyses.

The cyanide group released when cyanocobalamin is processed is detoxified by rhodanese using a sulfur donor, and molybdenum-dependent sulfite oxidase sits in the same sulfur-handling network. The quantity of cyanide involved at supplemental doses is very small. This is a mechanistic footnote rather than a practical pairing.